MetrioPharm Invest-Newsletter QII 2025

The 19th Annual General Meeting took place on June 16, 2025, in Zurich. With the annual report, the management and Board of Directors of MetrioPharm AG provided an overview of the company's activities in the 2024 fiscal year and an outlook on the company's further development.

Dr. Stephan Rietiker, who was elected Chairman of the Board of Directors in April 2025, introduced to the shareholders the newly formed Board of Directors and outlined the decision-making process since May.
In May 2025, the Board of Directors held several workshops with teams of specialists from MetrioPharm to gain a comprehensive insight into the status of preclinical and clinical development and to elaborate regulatory and strategic decisions. Several decisions had been subsequently made: Firstly, to explore the redevelopment of the formulation of MetrioPharm's lead compound MP1032 to achieve higher bioavailability and thus improved efficacy in studies. Secondly, to revise the strategic prioritization of clinical indications and to consider new indications. And thirdly, to reduce the burn rate by streamlining the organization.

The Board of Directors then provided an overview of the current financials and funding strategy, as well as risk mitigation strategies.

After approval of the annual report and financial statements for 2024 and the discharge of the Board of Directors, the auditors were elected. Finally, there was time for questions from shareholders and, following the Annual General Meeting, an opportunity to talk directly with management and members of the Board.

Of the total share capital of 209,908,275 registered shares with a par value of CHF 0.20, 172,565,343 shares were represented. This corresponds to 82.2% of the shares issued.